Trial Search Results

Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation

The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: perflutren lipid microspheres
  • Diagnostic Test: 3D ultrasound




Inclusion Criteria:

   - Ability to understand and willingness to sign the written informed consent document

   - Patient with primary liver tumor or metastasis scheduled for Stereotactic Ablative
   Radiotherapy (SABR)

   - Patient is at least 18 years of age. No gender/race-ethnic restrictions.

   - Performance status (ECOG) between 0-3

   - History and Physical done within 4 weeks of enrollment.

Exclusion Criteria:

   - Patient has previously been enrolled in and completed this study.

   - Known right to left cardiac shunt, bidirectional or transient.

   - Patient has any medical condition or other circumstances which would significantly
   decrease the chances of obtaining reliable data, achieving study objectives, or
   completing the study and/or post-dose follow-up examinations.

   - History of hypersensitivity to the contrast agent perflutren

   - History of pulmonary hypertension

   - Patients who are pregnant or are trying to become pregnant

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jen-Yeu Wang